Cognition announces publication of zervimesine manufacturing process

Cognition Therapeutics (CGTX) announced that the American Chemical Society journal Organic Process Research & Development has published a manuscript describing the novel chemical process used to manufacture zervimesine. With this new manufacturing process, Cognition will be able to produce materials for future clinical studies of zervimesine. In addition, if zervimesine is approved, this process is expected to support commercial manufacturing needs. Provisional patent applications covering this chemical process and a preferred polymorphic form of zervimesine have been filed.